It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative ...

Despite the perception of biopharma as a field that is slow to adopt new technology, artificial intelligence (AI) has been quietly improving the sector for years, from candidate prioritization in drug ...

Mesenchymal stem/stromal cells (MSCs) have been identified as a promising resource for cell therapies due to their high immunomodulation ability, anti-inflammatory properties, tissue regeneration ...